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A family with X-linked mental retardation characterized by severe mental retardation, speech and behavioral
abnormalities, and seizures in affected male patients has been found to have a G1141C transversion in the creatine-
transporter gene SLC6A8. This mutation results in a glycine being replaced by an arginine (G381R) and alternative
splicing, since the GrC transversion occurs at the 51 position of the 5′ splice junction of intron 7. Two female
relatives who are heterozygous for the SLC6A8 mutation also exhibit mild mental retardation with behavior and
learning problems. Male patients with the mutation have highly elevated creatine in their urine and have decreased
creatine uptake in fibroblasts, which reflects the deficiency in creatine transport. The ability to measure elevated
creatine in urine makes it possible to diagnose SLC6A8 deficiency in male patients with mental retardation of
unknown etiology.
X-linked mental retardation (XLMR) is composed of a
heterogeneous group of entities that accounts for 5%–
12% of all mental retardation, depending on the method
of estimation (Stevenson et al. 2000). XLMR entities
can be separated into two groups: syndromic (MRXS)
and nonsyndromic (MRX) mental retardation (Neri et
al. 1991). The separation is based on the presence (in
MRXS) or absence (in MRX) of distinctive somatic, met-
abolic, or neurological features associated with the men-
tal retardation. Both MRXS and MRX have been lo-
calized to all regions of the X chromosome (Lubs et al.
1999; Chiurazzi et al. 2001). One such region is Xq28,
to which 11 MRXS and 8 MRX conditions have been
mapped (Armfield et al. 1999; Chelly 2000). This region
is also gene rich, which makes it difficult to choose can-
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didate genes for screening in families with XLMR. None-
theless, some success has been achieved by utilization of
the positional cloning approach. L1CAM (L1 cell-ad-
hesion molecule) was identified as the gene involved in
X-linked hydrocephalus (Rosenthal et al. 1992), MASA
syndrome (Vits et al. 1994), and X-linked agenesis of
corpus callosum (Jouet et al. 1994). Mutations in the
gene that encodes GDI1, a GDP-dissociation inhibitor,
have been found to be responsible for MRX41 and
MRX48 (D’Adamo et al. 1998). The gene that encodes
MECP2, a methyl-CpG-binding protein, has also been
shown to be involved in Rett syndrome (Amir et al.
1999) and MRX16 (Couvert et al. 2001) and has been
implicated in some families with XLMR in which male
patients have severe mental retardation (Meloni et al.
2000; Orrico et al. 2000; Couvert et al. 2001).
A partial pedigree of family K8085 is shown in figure
1a, with five affected male patients in one generation.
All affected male patients, except II-8, underwent a clin-
ical examination as described by Schwartz (1993). Clin-
ical information on II-8 was taken from his medical re-
cords. Summaries of the clinical findings are given in
table 1. All affected male patients had severe mental
retardation with speech and behavioral abnormalities,
Figure 1 Linkage and segregation analysis of family K8085. a, Partial pedigree of family K8085, showing haplotype with 11 DNA loci
located in Xq28. Microsatellite analysis was conducted using an automated laser fluorescent (ALF) sequencer (Amersham-Pharmacia), as described
elsewhere (Stevenson et al. 1998). Boxed numbers indicates the at-risk haplotype associated with mental retardation. Blackened squares denote
affected male patients, and blackened circles denote female carriers with phenotypic expression; a minus sign () above a symbol indicates that a
blood sample was obtained for analysis. b, BsaAI analysis of the G1141C alteration in SLC6A8. Presence of the G1141C alteration is reflected in
the presence of bands of 221 and 88 bp. Numbers above each lane refer back to the pedigree in panel a. Lp size marker. For segregation analysis,
intron-specific primers 8085IF (5′-AGTAAGCACCGCCGCCCTG-3′) and 8085IR (5′-TTTCAGCATTTCTATTGCATGTTC-3′) were designed to
amplify exon 7 of SLC6A8, producing a product of 309 bp. PCRs were performed in a 30-mL volume that contained 52.5 ng genomic DNA, 1X
Master Amp Buffer J (Epicentre), 50 mM dNTPs, 1 mM each primer, 1.5 U Sigma Taq polymerase (Boehringer Mannheim), and 0.33 mg TaqStart
antibody (Clonetech). Annealing was done for 30 s at 58C, extension for 30 s at 72C, and the PCR was repeated for 30 cycles. PCR products
were digested with BsaAI (New England Biolabs) for 16 h at 37C with 10 U enzyme in buffer supplied by the manufacturer. Spermidine was added
to a final concentration of 1 mM prior to digestion. Digested fragments were resolved by electrophoresis in a 2% agarose gel that contained ethidium
bromide.
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Table 1
Summary of Clinical Findings
MALE PATIENTS
Affected
II-11
(Unaffected)
FEMALE
PATIENTS
II-5 II-6 II-7 II-8 II-16 II-12 II-13
Age at examination (years) 66 53 62 15 35 56 37 39
Height (cm) [percentile] 167.5 [10] 162.5 [3] 162.5 [3] 162.5 [25] NA 175.5 [50] NA NA
Head circumference (cm) [percentile] 55 [30] 56.5 [60] 54.5 [25] 53.5 [25] 55.3 [40] 58.6 [90] NA NA
Ear length (cm) 7.5 7.3 7.3 NA 6.3 NA NA NA
Midface hypoplasia    NA   NA NA
Stub thumb    NA   NA NA
Hyperextensible joints    NA   NA NA
Hypotonia  NA  NA   NA NA
Gastrointestinal problem       25 NA
Seizures        
Movement disorder       NA NA
Speech problem        
Behavior disturbance        
Intelligence quotient 16 4 4 NA 9 NA 69 67
Urine creatine:creatinine ratioa 2.5 NA 1.7 NA NA .4 NA NA
Creatine uptakeb (pmol creatine/mg protein) 6.2 ND 6.9 ND ND ND ND ND
NOTE.—NA p not available; ND p not determined.
a Urinary creatine was measured using capillary electrophoresis as described by Clark et al. (2001). A Beckman Pace MDQ capillary
electrophoresis system was utilized for electrophoresis, and creatinine and creatine were monitored using a UV detector. Peak heights and
migration times were calculated using Beckman software on an IBM 486 computer. A 50-mM phosphate buffer at pH 5.5 was used as the run
buffer. The urine-dilution buffer consisted of the run buffer supplemented with 2% EDTA. The 0.020-mm capillary was 50 cm long (J&W
Scientific). Each run included a 3-min wash with 1N NaOH followed by a 1-min wash with distilled water and a 3-min wash with run buffer.
Each sample was injected for 5 s (20 psi) and was electrophoresed for 8 min at 25 kV. Absorbance was monitored at 214 nm. Urine was
diluted 1:1 with the urine-dilution buffer and was electrophoresed. A set of standards for both creatine and creatinine were loaded with each
sample run. Known concentrations were 0.5 mM, 1 mM, 2.5 mM, 5 mM, 7.5 mM, and 10 mM. For each sample, the concentration of both
creatine and creatinine were calculated using standard curves derived from the set of standards. The creatine:creatinine ratio was calculated
for both affected patients and the unaffected brother and control subjects.
b Creatine uptake in fibroblasts was measured after a 24-h incubation in 500 mM creatine as described elsewhere (Salomons et al. 2001).
The average uptake levels in two controls was 15.8 pmol creatine/mg protein.
as well as a history of seizures. Head circumference was
normal in all affected male patients. Adult height
(162.5–167.5 cm) was less than the adult height of the
unaffected brother (175.5 cm). Midface hypoplasia, un-
folded superior helices, soft skin, hyperextensible joints
and hypotonia in the upper limbs, stub thumbs, and pes
cavus occurred in some affected male patients. Gastro-
intestinal disturbances in the form of chronic consti-
pation, megacolon, gastric and duodenal ulcer disease,
ileus, and bowel perforation were common. The geni-
talia were normal, although inguinal hernias occurred
in two affected male patients. Motor tone in the upper
limbs was lower than that in the lower limbs, in two
individuals. II-7 had combined spastic/dystonic gait and
choreoathetoid/dystonic movements of the face and up-
per limbs, as well as a history of neuroleptic malignant
syndrome. Two sisters (II-12 and II-13) of the affected
male patients had mild cognitive impairment, and one
(II-13) had chronic behavioral disturbances. No infor-
mation was available on I-2, an obligate carrier.
Two-point linkage analysis (Lathrop and Lalouel
1984) by use of 34 DNA markers spanning the X chro-
mosome indicated linkage of XLMR in family K8085
to Xq28, since seven markers had a LOD score of 2.40
at zero recombination (data not shown). Recombination
occurred in an unaffected brother (II-11) between
DXS8091 and DXS113, thereby establishing DXS8091
as the limiting proximal flanking marker in Xq28 (fig.
1a).
Once linkage to Xq28 was established, candidate-
gene testing was initiated. Twelve genes (FRAXA,
FRAXE, MECP2, LICAM, GLUR3, GABRA3,
GABRE1, VATPS1, XAP3, XAP5, XAP6, and
SYBL1) were tested. However, no causative mutations
were found (C. E. Schwartz, unpublished data). After
a report appeared that a nonsense mutation (R514X)
in the creatine-transporter gene, SLC6A8 (MIM
300036; GenBank accession number NM_005629;
Nash et al. 1994), was observed in DNA from a mildly
retarded boy and in DNA from three female
relatives—two of whom showed learning disabilities
(Cecil et al. 2001; Salomons et al. 2001)—this gene
was examined since it fell within the linkage interval.
cDNA analysis of lymphoblasts of male patient II-5
was undertaken. Primers were used to amplify a 1.6-kb
fragment, which contained the translated region minus
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exon 1 (Salomons et al. 2001). This template was em-
ployed for a seminested PCR of 5′ and 3′ fragments of
1.1 kb and 530 bp, respectively. Direct sequence analysis
of the sense strand of the 5′ fragment consisting of exons
2–8 indicated the apparent existence of a mixed popu-
lation of amplicons, because of unreadability of the se-
quence after base 1130 (GenBank accession number
NM_005629; data not shown). Primers were then de-
signed to amplify a 250-bp cDNA product spanning nu-
cleotides 1020–1269. Gel electrophoresis of this ampli-
con revealed the expected band of 250 bp, as well as a
smaller band of 237 bp, in three members of family
K8085. The 237-bp band was absent in a control sample
(fig. 2a). The cDNA PCR product from patient II-5 was
subcloned, allowing purification of the two different
PCR fragments (fig. 2a). Sequence analysis of the 250-
bp fragment revealed the presence of a GrC transversion
at position 1141 (fig. 2b). The smaller fragment was
found to contain a deletion of 13 bp (positions 1129–
1141; fig. 2b). Sequencing of the genomic DNA from
male patients II-3 and II-5 confirmed the G1141C al-
teration (data not shown). This GrC alteration gives
rise to an arginine substitution for a glycine at position
381 (G381R).
Additionally, the G at nucleotide position 1141 oc-
cupies the 1 base for the 5′ splice site of intron 7.
Comparison of the sequence of the lower-sized transcript
with the genomic sequence indicated that the 13-bp de-
letion likely resulted from utilization of an alternative
upstream splice site within exon 7 (fig. 2c). The consen-
sus value (CV) of this splice junction (AGgtggca) is
0.661, which is 93% of the CV of 0.712 for the splice
junction (ACgtaggg) that contains the 1141 GrC trans-
version (Cooper and Krawczak 1995).
The G1141C change creates a BsaAI site in the mutant
genomic DNA. BsaAI digestion of amplified genomic
DNA was used to confirm the sequence data and to check
for segregation of the mutation in family K8085. As seen
in figure 1b, the mutation did segregate with XLMR in
family K8085, and the presence of the BsaAI site was
consistent with the haplotype data that was derived from
the linkage analysis (fig. 1a). Furthermore, BsaAI diges-
tion of 400 X chromosomes from unaffected male indi-
viduals failed to detect this alteration, indicating the GrC
transversion was likely not a rare polymorphism.
Subsequent biochemical analyses confirmed a defect
in creatine metabolism in family K8085. The level of
urinary creatine was substantially increased in affected
male patients II-3 and II-5. Their urinary creatine:cre-
atinine ratios were 2.5 and 1.73, respectively, whereas
the ratio for their unaffected brother (II-9) was 0.39
(table 1). This ratio ranged from 0.3 to 0.7 in eight adult
control subjects.
Creatine uptake in fibroblasts from patients II-5 and
II-7 was measured after a 24-h incubation in the presence
of either a physiological level of 25 mM or a higher level
of 50 mM creatine (Salomons et al. 2001). No uptake
could be measured in the presence of 25 mM creatine,
and, at 500 mM, the level of uptake was approximately
one-fourth that of control cells (table 1).
The G114C transversion in SLC6A8 has two effects:
1. The base substitution gives rise to a missense mu-
tation in which glycine is replaced by arginine at position
381 (G381R). G381 is part of a sequence of 12 invariant
amino acids (VAASGPGLAFLA), which is conserved
among related proteins in several species (fig. 3). This
strong conservation likely reflects the important nature
of this region of the gene.
2. The G1141C transversion occupies the1 position
of the exon 7/intron 7 splice junction. Substitution of
the cytosine results in a substantial reduction in the CV
of the splice junction, from 0.847 to 0.712 (Cooper and
Krawczak 1995). This, in turn, causes an alternative
splice site upstream at position 1129 to be utilized part
of the time, since its CV of 0.661 is close in value (ratio
 1.02). Utilization of the alternative splice site causes
a deletion of 13 bp, which would cause a substitution
of 14 novel amino acids and truncation of the protein
at position 390 (fig. 2c). As a result, a large portion of
the 3′ end of the protein, containing 145 amino acids
that comprise transmembrane (TM) domains 8–12 as
well as the carboxy end, would be absent from the
SLC6A8 protein.
The clinical presentation (i.e., severe mental retarda-
tion with speech and behavioral abnormalities, seizures,
variable short stature, and midface hypoplasia) of the
male patients with the G1141C mutation in SLC6A8 is
more severe than the presentation by the mildly mentally
retarded boy with a nonsense mutation (R514X) in
SLC6A8, who has been described elsewhere (Cecil et al.
2001; Salomons et al. 2001). This may reflect a geno-
type-phenotype correlation. The R514X mutation re-
sults in a truncated protein missing TM domains 11 and
12, as well as the cytoplasmic carboxy end of the gene.
The presence of creatine-transporter molecules that con-
tain the G381R missense mutation may lead to a dom-
inant negative effect and a more severe presentation of
the disease in family K8085 when compared with the
presence of only a nonsense mutation in the previously
reported male patient with the R514X mutation. How-
ever, studies of in vitro creatine uptake in fibroblasts
from two male patients in family K8085 and from the
male patient with the R514X mutation showed equal
impairment in creatine uptake, both when cultured in a
physiological level of creatine of 25 mM and at a higher
level of 500 mM. Alternatively, severe mental retarda-
tion in the men in family K8085 may reflect the possible
progressive nature of long-term low cellular-creatine lev-
Figure 2 RT-PCR analysis of exons 7 and 8 of the SLC6A8 cDNA. a, Agarose gel electrophoresis of RT-PCR products generated with
lymphoblasts from patients II-2, II-5, and II-7 and from a control subject. RT-PCR products from patient II-5 were subcloned, allowing purification
of the two different amplicons (i.e., subclones A and B). b, Sequence analysis of RT-PCR product from a control subject, subclone A from patient
II-5, and subclone B from patient II-5. The letters “G” and “C” atop a yellow screen, in the normal and subclone A diagrams, respectively, indicate
the GrC transition at position 1141. The amino acids in boldface indicate the G381R missense mutation that results from the G1141C alteration.
The arrow in the subclone B diagram indicates the location of the 13-bp deletion in the RT-PCR subclone from patient II-5. The two letters “G”
atop a blue screen, in the normal and subclone B diagrams, indicate the position of the deletion relative to the normal exon 7 sequence. The novel
amino acids that are substituted as a result of the 13-bp deletion are in italic. c, The alternative 5′ splice site in exon 7 predicted in family K8085.
An arrow indicates the splice site. The predicted amino acid sequence for the altered SLC6A8 protein is given below the novel mRNA sequence.
Total RNA was extracted from lymphoblastoid cell lines (∼ cells) by use of TRIzol LS (Life Technologies) according to the manufacture’s63 # 10
protocol. Samples were treated with DNase I/Amp (Life Technologies) for 15 min at room temperature and were purified using the RNeasy Mini
Kit (QIAGEN). Approximately 3 mg total RNA was reversed transcribed into cDNA by use of random hexamers (Super Script Preamplification
System; Life Technologies). Primers 8085F (5′-GCCATCATCCTGGCTCTCATC-3′) and 8085R (5′-CCTCCACACCTACAAACTGGC-3′) were
designed, flanking the region of the presumed cDNA alteration in family K8085, which produced an amplicon of 250 bp. PCR was performed in
a 50-mL volume containing 105 ng cDNA, 1X Sigma buffer (Boehringer Mannheim), 50 mM dNTPs, 10 mM each primer, 1.5 U Sigma Taq
polymerase, and 0.33 mg TaqStart antibody. Amplification was done in a 9600 Thermocycler (Perkin Elmer/Cetus) by use of the following parameters:
3 min at 96C, 30 s at 94C, annealing for 30 s at 67C, extension for 30 s at 72C for 30 cycles, and a final extension for 7 min at 72C. PCR
products were checked by electrophoresis on an 8% acrylamide/15% glycerol minigel (Hoefer). Products were purified using the Qiagen PCR
Purification Kit (Qiagen). Amplicons were cloned into Escherichia coli One Shot INVaF′ competent cells using the Original TA Cloning Kit
(Invitrogen). Clones containing the insertion were detected using LB ampicillin agar plates containing X-gal. Colonies containing the insertion were
grown overnight in 5 ml LB broth containing ampicillin. Plasmid DNA was isolated using the Qiagen Spin Miniprep Kit (Qiagen). Direct sequence
analysis of RT-PCR products was performed using Bigdye terminators and analysis on an ABI 310 machine (Perkin Elmer). Subcloned cDNA was
sequenced using a Thermo Sequenase fluorescent-labeled primer cycle sequencing kit (Amersham) and FAM (5-fluorouracil, Adriamycin, and
mitomycin C)–labeled M13 (40) forward and reverse primers (Pharmacia Biotech) and the ALF DNA sequencer.
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Figure 3 Comparison of a partial amino acid sequence of SLC6A8 and with other members of the taurine-subfamily transporters. The
presented amino acid sequence covers the extracellular domain between TM domains 7 and 8. The glycine at position 381 is shaded, and the
12 invariant amino acids are underlined.
els, although the limited history available on the male
patients did not reveal any cognitive regression.
The presence of a mutation in SLC6A8 may result in
muscle weakness or other symptoms of muscle impair-
ment due to an inability to generate ATP from phos-
phocreatine. The hypotonia and myopathic facies, in one
male patient, and ptosis, in another, are suggestive of
muscle involvement. The hypotonia could be cerebral in
origin, as are the extrapyramidal movements. Unfortu-
nately, no muscle studies were conducted to determine
if muscle pathology existed, and studies of muscle pa-
thology and function were not conducted in the patient
with a creatine transporter defect, who has been de-
scribed elsewhere (Salomons et al. 2001). Since the
1930s, an excess of male patients has been noted in the
population with mental retardation (Penrose 1938). This
excess has been attributed to genes on the X chromo-
some (Lehrke 1974; Turner and Turner 1974; Stevenson
et al. 1990). This concept has been supported by the
clinical and molecular delineation of numerous syn-
dromic and nonsyndromic forms of XLMR (Schwartz
1993; Chelly 2000). However, the recognized forms of
XLMR do not account for the 20%–40% excess of male
patients who have been reported in the major surveys
conducted over the past 20 years. An excess of 30%
should result in a frequency of 15% for all cases of
mental retardation. However, the major surveys of men-
tal retardation report !5% of cases resulting from
XLMR (Moser and Wolf 1971; Kaveggia et al. 1975;
Gustavson et al. 1977; Laxova et al. 1977; Hunter et
al. 1980; Anderson et al. 1996).
Numerous factors may be responsible for the differ-
ence between the estimated prevalence and the detectable
prevalence of XLMR: First, many XLMR entities are
nonsyndromic (i.e., MRXS), and, thus, physical exam-
ination provides no clues for clinical diagnosis. Second,
if a significant proportion of XLMR is due to new mu-
tations, the pedigree information will not suggest X-
linked inheritance. Third, very few entities have asso-
ciated metabolic abnormalities, which might bring them
to attention.
There are seven genes associated with MRXS—
IRL1RAP, TM4SF2, OPHN1, PAK3, ARHGEF6,
FMR2, and GDI1 (Chelly and Mandel 2001)—and
three genes associated with MRX—RSK2 (Merienne
et al. 1999), MECP2 (Meloni et al. 2000; Orrico et
al. 2000; Couvert et al. 2001), and FGD1 (Lebel et
al., in press). Perhaps with the exception of RSK2,
defects in these genes are not detectable by use of a
biochemical or metabolic assay. Identification of a
XLMR entity that is associated with a mutation in
the creatine transporter will allow testing for SLC6A8
mutations in male patients with mental retardation of
unknown etiology.
This report, in conjunction with the that of publica-
tion of a report of two female siblings with arginine:
glycine amidinotrasferase (AGAT) deficiency (Item et al.
2001) and those of the already known guanidinoacetate
methyltransferase (GAMT) deficiency (Sto¨ckler et al.
1996; Von Figura et al. 2000), clearly indicates the im-
portance of creatine metabolism in brain function. In all
three errors of creatine metabolism, mental impairment
of varying degree is observed. This would be in agree-
ment with already-existing literature that creatine me-
tabolism plays a significant role in brain function beyond
its use as a high-energy phosphate store. There is evi-
dence that there exists direct coupling of creatine kinase
with neurotransmitter release (Wallimann and Hemmer
1994), with growth cone migration (Wang et al. 1998)
and restoration of ion gradients before and after de-
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polarization (Wallimann and Hemmer 1994). Thus,
brain function appears to be linked in a number of ways
with creatine metabolism, although the relationships are
not yet fully understood.
All three errors of creatine-metabolism conditions
lend themselves to biochemical tests, since guanidinoac-
etate and creatine levels can be measured in either urine
or plasma. As a result, diagnosis of these inborn-error
disorders can be made, which is important, since two of
them, AGAT and GAMT deficiencies, may be amenable
to oral creatine supplementation (Sto¨ckler et al. 1996;
Item et al. 2001).
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